Sanofi doesn't have many patent cliffs to worry about. Lantus now competes with biosimilars and its growth has since stalled. Plavix succumbed to generic competition years ago in the U.S., but is ...

Free cash flow for 2024 was €6 billion, impacted by Lantus price cuts, elimination of receivables ... Beyfortus with new ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Sanofi raised the price of Lantus from $50 a vial in 2006 to $340 in 2023. If insulin is too expensive, patients may avoid ...

He said that when Sanofi's senior decision-makers convene ... The pharmaceutical company, which makes drugs like Lantus insulin jabs and Plavix blood thinners, spends about three billion euros ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Sanofi SNY reported fourth-quarter 2024 adjusted ... In Others, Toujeo recorded sales of €290 million, up 6.5% year over year. Lantus sales rose 63.4% to €439.0 million. SNY & AZN’s ...

It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India.